Resources Blog Antibody Isotypes: IgD

Antibody Isotypes: IgD

Biointron 2024-01-20 Read time: 3 mins
IgD.jpg
Image credit: DOI: 10.1007/s11882-016-0658-x

Immunoglobulin D constitutes approximately 0.25% of all serum immunoglobulins in the body, and there is still debate over the specific role for IgD. There is evidence suggesting they may play a part in basophil and mast cell activation to produce antimicrobial factors, as well as determining if antigens will activate B cells.1

In humans, although most mature B cells express both surface IgD and IgM by alternative splicing of preRNA, a small group of mucosal B cells from the nasopharyngeal lymphoid tissue expresses solely IgD. This secreted IgD can be found in circulation, nasopharyngeal, oral and lachrymal secretions, in addition to being on the surface of myeloid innate effector cells, such as basophils, mast cells and monocytes. When IgD is basophil-bound and cross-linked by an antigen, the release of cytokine IL-4 will trigger an increase in IgG production, thus enhancing humoral immunity by the mucosal immune surveillance.2

Moreover, the IgD molecule has a lengthy hinge region between Fab and Fc, which is the likely cause for IgD to be susceptible to proteolysis, although this increases flexibility and thus improves antigen binding. Interestingly, the hinge region also appears to regulate the responsiveness of B cells, as Übelhart et al. (2015) discovered when deleting it resulted in IgD being reactive to monovalent antigens, while transferring the hinge to IgM resulted in responsiveness only to polyvalent antigens.3 

Meanwhile, serum IgD is thought to represent an early marker of B-cell activation. Other potential functions of IgD include having a regulatory role, the generation and maintenance of B-cell memory, and as an inducer of TNF-α, IL-1β, and IL-1 receptor antagonist. Furthermore, serum IgD measurement can be important for monitoring of IgD myelomas by measuring the protein concentration of the M spike in serum protein electrophoresis.2

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References: 

  1. Vladutiu, A. O. (2000). Immunoglobulin D: Properties, Measurement, and Clinical Relevance. Clinical and Diagnostic Laboratory Immunology, 7(2), 131. https://doi.org/10.1128/CDLI.7.2.131-140.2000

  2. Gutzeit, C., Chen, K., & Cerutti, A. (2018). The enigmatic function of IgD: some answers at last. European Journal of Immunology, 48(7), 1101–1113. https://doi.org/10.1002/EJI.201646547

  3. Übelhart, R., Hug, E., Bach, M. P., Wossning, T., Dühren-Von Minden, M., Horn, A. H. C., Tsiantoulas, D., Kometani, K., Kurosaki, T., Binder, C. J., Sticht, H., Nitschke, L., Reth, M., & Jumaa, H. (2015). Responsiveness of B cells is regulated by the hinge region of IgD. Nature Immunology 2015 16:5, 16(5), 534–543. https://doi.org/10.1038/ni.3141

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024
Blog

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024
Blog

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024
Blog

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024
Blog

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.